



Covered for your TRICARE® patients

- Rayaldee® is available for a \$68 copay for up to a 90-day supply via **TRICARE® Pharmacy Home Delivery***
- Rayaldee® is available for a \$68 copay for up to a 30-day supply via **TRICARE® retail network pharmacy**
- Active Duty Service Members have no prescription drug cost (\$0) when using a military pharmacy, TRICARE® Pharmacy Home Delivery, or a TRICARE® retail network pharmacy for covered drugs

*Rayaldee is available for a \$34 copay for up to a 90-day supply via TRICARE Pharmacy Home Delivery if Rayaldee is determined to be medically necessary. The prescriber must complete, sign and submit the [TRICARE Pharmacy Program Medical Necessity Form for Vitamin D Analogs: Calcifediol \(Rayaldee\)](#).

Download a PDF of the Medical Necessity Form at <https://rayaldee.com/wp-content/themes/rayaldee/pdfs/hcp/tricare-rayaldee-letter-of-medical-necessity.pdf> or scan the QR code at the right to download.

Source: TRICARE® Costs and Fees 2022, <https://www.tricare.mil/publications>, <https://www.express-scripts.com/frontend/open-enrollment/tricare/fst/#/formularyPricing/home> / Date accessed: July 2022.

SCAN CODE



Call OPKO CONNECT at **1-844-414-OPKO** to speak with a Rayaldee® Support Specialist Monday-Friday from 8 am to 8 pm ET or email **OPKOCONNECT@RXALLCARE.COM.**

Indication and Limitations of Use

Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

Important Safety Information

• **Hypercalcemia:** Excessive administration of vitamin D compounds, including Rayaldee, can cause hypercalcemia and hypercalciuria. Severe hypercalcemia due to substantial overdosage of vitamin D and its metabolites may require emergency attention. Patients should be informed about the symptoms of elevated calcium. • **Digitalis toxicity:** Potentiated by hypercalcemia of any cause. Monitor serum calcium and signs and symptoms of digitalis toxicity more frequently when initiating or adjusting the dose of Rayaldee. • **Adynamic Bone Disease:** Monitor for abnormally low levels of intact parathyroid hormone (iPTH) levels when using Rayaldee, and adjust dose if needed. • The most common adverse reactions (≥3% and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation. • Care should be taken while dosing Rayaldee with cytochrome P450 inhibitors, thiazides, cholestyramine or drugs stimulating microsomal hydroxylation due to the potential for drug interactions. • Serum calcium should be below 9.8 mg/dL before initiating treatment. • Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and iPTH 3 months after starting therapy or changing dose.

For Full Prescribing Information, visit www.Rayaldee.com.

OPKO RENAL
A DIVISION OF OPKO HEALTH, INC.

RAYALDEE® is a registered trademark of Eirgen Pharma Ltd. OPKO Renal is a division of OPKO Health, Inc. © 2022 OPKO Pharmaceuticals, LLC. All rights reserved.

TRICARE is a registered trademark of the Department of Defense (DoD), Defense Health Agency (DHA). All rights reserved. OP-US-0478-082022v.3